期刊文献+

卵巢癌卡铂耐药相关肿瘤抑制基因差异表达的研究 被引量:2

Differential Expression of Tumor Suppressor Gene in Carboplatin Resistance Microarray of Ovarian Carcinoma
下载PDF
导出
摘要 目的分析卵巢癌卡铂耐药基因芯片中卡铂耐药细胞系SKOV3-CB较其亲本SKOV3细胞系差异表达下调的肿瘤抑制基因,并验证其差异表达。方法应用分子生物信息学方法 ,分析基因芯片中卵巢癌SKOV3-CB细胞系较SKOV3细胞系差异表达下调两倍以上的基因1554条,筛选出肿瘤抑制基因17个,即:RNASET2,VHL,DLG1,COPS2,NOL7,GGNBP2,RBL1,S100A2,PARG1,PERP,TCF3,DNAJA3,PCGF2,ING1,CYLD,RARRES3,RBBP8,应用荧光定量PCR技术对差异表达进行验证。结果 RNASET2,VHL,DLG1,COPS2,NOL7,RBL1,S100A2,PARG1,PERP,TCF3,DNAJA3,ING1,CYLD,RARRES3,RBBP8基因差异表达下调,下调倍数分别为24.47、65.24、10.81、21.30、72.94、5.95、27.13、1.57、1.32、12.93、46.80、7.57、14.90、14.00、23.98。GGNBP2,PCGF2,DLG1基因差异表达上调,上调倍数分别为5.76、2.19和17.10,基因芯片差异表达结果与real-timePCR所验证表达下降趋势的结果符合率为82.35%,下调两倍以上的基因符合率为64.70%。结论利用基因芯片技术分析基因差异表达,结合real-timePCR对其检测结果验证是一种有效的方法 ,多肿瘤抑制基因参与卵巢癌卡铂耐药的机制。 Objective To analyze the down-regulated tumor suppressor gene of differential expressions of carboplatin resistance cell line SKOV3-CB and its parental cell line SKOV3 in ovarian cancer carboplatin resistance gene array.Methods Using molecular bioinformatics methods to analyze 1554 over-2-fold-downregulated genes of the differential expressions of ovarian cancer SKOV3-CB cell lines and SKOV3 cell lines,and 17 tumor suppressor genes (RNASET2,VHL,DLG1,COPS2,NOL7,GGNBP2,RBL1,S100A2,PARG1,PERP,TCF3,DNAJA3,PCGF2,ING1,CYLD,RARRES3,RBBP8) were screened out,and the differential expressions were verified by real-time quantitative PCR technique.Results The differential expressions of genes RNASET2,VHL,DLG1,COPS2,NOL7,RBL1,S100A2,PARG1,PERP,TCF3,DNAJA3,ING1,CYLD,RARRES3,RBBP8 were down regulated,the multiples of which were 24.47,65.24,10.81,21.30,72.94,5.95,27.13,1.57,1.32,12.93,46.80,7.57,14.90,14.00,23.98,respectively.The differential expressions of genes GGNBP2,PCGF2,DLG1 were up regulated,the multiples of which were 5.76,2.19,17.10,respectively.The coincidence of the results of gene microarray differential expressions with those of downward trend of expressions validated by real-time PCR was 82.35%,that of genes down-regulated 2 folds was 64.70%.Conclusion The gene differential expression analysis by cDNA microarray technique combined with test result verification by real-time PCR is an effective method.Multiple tumor suppressor genes were involved in carboplatin resistance mechanism of ovarian cancer.
出处 《中国全科医学》 CAS CSCD 北大核心 2010年第21期2338-2341,共4页 Chinese General Practice
基金 广西壮族自治区卫生厅重点科研课题基金资助(重200865) 广西研究生教育创新计划资助项目(2009105981002D26)
关键词 卵巢肿瘤 抗药性 肿瘤 芯片分析技术 基因 肿瘤抑制 Ovarian neoplasms Drug resistence neoplasm Microchip analytical procedures Genes tumor suppressor
  • 相关文献

参考文献10

  • 1Watanabe Y,Ueda H,Etoh T,et al.A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer[J].Anticancer Res,2007,27(3B):1449-1452.
  • 2Staub J,Chien J,Pan Y,et al.Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance[J].Oncogene,2007,26 (34):4926-4978.
  • 3栾英姿,李力,黎丹戎,张玮,唐步坚.五种卵巢癌耐药细胞系的建立及其部分耐药相关基因的表达[J].中华妇产科杂志,2004,39(6):403-407. 被引量:21
  • 4张文晶,李红霞,宋磊,张素梅.应用基因芯片技术筛选卵巢癌紫杉醇耐药差异表达基因[J].肿瘤防治研究,2006,33(1):32-35. 被引量:5
  • 5Vase PA.Resistance to chemotherapy in advanced ovarian cancer:mechanisms and current strategies[J].Br J Cancer,2003,89 (Suppl3):S23.
  • 6Zhou C,Smith JL,Liu J.Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1[J].Oncogene,2003,22(16):2396-2404.
  • 7Metzinger DS,Taylor DD,Gercel-Taylor C,et al.Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines[J].Cancer Lett,2006,236(2):302-328.
  • 8罗瑶,许宏,李瑶,韩志勇,裘敏燕,陈沁,刘三震,倪胜,谢毅,毛裕民.表达谱基因芯片的可靠性验证分析[J].Acta Genetica Sinica,2003,30(7):611-618. 被引量:11
  • 9Hembruff SL,Villeneuve DJ,Parissenti AM,et al.The optimization of quantitative reverse transcription PCR for verification of cDNA microarray data[J].Anal Biochem,2005,345(2):237-249.
  • 10Chaib H,Cockrell EK,Rubin MA,et al.Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cdna microarray analysis[J].Neoplasia,2001,3 (1):43-52.

二级参考文献50

  • 1Krauer K G, Buck M, Belzer D K, et al. The Epstein Parr virus nuclear antigen-6 protein co-localizes with EBNA-3 and survial of motor neurons protein[J]. Virology, 2004,318(1) :280-294.
  • 2Krauer K G, Burgess A, Buck M, et al. The EBNA 3 gene family proteins disrupt the G2/M checkpoint [J]. Oncogene,2004, 23(7):1342-1353.
  • 3Bech-Otschir D, Seeger M,Wolfgang D, et al. The COP9 signalosome: at the interface between signal transduction and ubiquitin-dependent proteolysis[J]. J Cell Sci, 2002, 115 (Pt 3) : 467-473.
  • 4Bech-O D, Kraft R, Huang X, et al. COP9 signalsome-specific phosphorylation targets p53 to degradation by the ubiquitin system[J]. J EMBO, 2001, 20(5): 1630-1639.
  • 5Seeger M, Kraft R, Ferrell K, et al. A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits[J]. J FASEB, 1998, 12(3) : 469-478.
  • 6Kobayshi M, Sugumaran G. Molecular cloning and characterization of a human uron sulfotransferase that sulfates iduronyl and glucurony residues in dermatan/chondroitin sulfate[J]. J Biol Chem, 1999, 274(15):10474-10480.
  • 7Bockenhauer D, Zilberberg N, et al. KCNK2: reversible conversion of a hippocampal potassium into a voltage-dependent channel[J]. Nat Neurosci, 2001 , 4(5): 457-458.
  • 8Xie S, Lin H, Sun T, et al. Jak2 is involved in c-Myc induction by Bcr-Ab1[J]. Oncogene, 2002,21 (47) : 7137-7146.
  • 9Morimoto RI. Regulation of the heat shock transcriptional response cross talk between a family of a heat shock factors, molecular chaperones, and negative regulatiors[J]. J Genes Dev,1998, 12(1): 3788-3796.
  • 10Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death[J]. J Natl Cancer Inst. 2000, 92(1 ) : 1564-7154.

共引文献33

同被引文献28

  • 1Chang S J, Bristow RE, Ryu HS. Impact of complete cytoreduction leav- ing no gross residual disease associated with radical cytoreduetive surgical procedures on survival in advanced ovarian cancer [ J ]. Ann Surg On- col, 2012, 19 (13): 4059-4067.
  • 2Chereau E, Lavoue V, Ballester M, et al. External validation of a lapa- roscopie - based score to evaluate respectability for patients with ad- vanced ovarian cancer undergoing interval debulking surgery E J ]. Anti- cancer Res, 2011, 31 (12) : 4469 -4474.
  • 3Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky ad- vanced stage ovarian, tubal, and peritoneal carcinoma treated with pri- mary debulking surgery (PDS) during an identical time period as the randomized EORTC - NCIC trial of PDS vs neoadjuvant chemotherapy (NACT) [J]. Gyneeol Oncol, 2012, 124 (1): 10-14.
  • 4Dewdney SB, Rimel B J, Reinhart AJ, et al. The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer : survey results from members of the society of gynecologic oncolo- gists [J]. Gynecol Oncol, 2010, 119 (1): 18-21.
  • 5Fags - Olsen CL, Hgtkansson F, Antonsen SL, et al. Diagnostic accu- racy of risk of malignancy index in predicting complete tumor removal at primary dehulking surgery-for ovarian cancer patients [ J]. Acta Obstet Gynecol Scand, 2013, 92 (6): 721-726.
  • 6Freedman OC, Dodge J, Shaw P, et al. Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy [ J ]. Gynecol Oncol, 2010, 119 (1): 22-25.
  • 7Vergote I, Trop6 CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage ~[C or 1V ovarian cancer [J]. N Engl J Med, 2010, 363 (10): 943-953.
  • 8Furukawa N, Sasaki Y, Shigemitsu A, et al. CA - 125 cut - off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer [ J ]. J Gynecol Oncol, 2013, 24 (2): 141-145.
  • 9Keyver - Paik MD, Zivanovic O, Rudlowski C, et al. Interval debulk- ing surgery in patients with Federation of Gynecology and Obstetrics (FIGO) stage RIC and 1V ovarian cancer [J]. Onkologie, 2013, 36 (6) : 324 -332.
  • 10Luyckx M, Leblanc E, Filleron T, et al. Maximal cytoreduction in pa- tients with FIGO stage ~[ C to stage 1V ovarian, fallopian, and perito- neal cancer in day - to - day practice: a Retrospective French Multi- centric Study [J]. Int J Gynecol Cancer, 2012, 22 (8): 1337- 1343.

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部